Smecta (Bentonite)

Bentonite

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Smecta (Bentonite)

Property	Description
Active ingredient	Diosmectite (Dioctahedral Smectite)
Form	Powder for oral suspension (sachets)
Pharmacological class	Intestinal Adsorbent and Gastrointestinal Protectant
General purpose	To stabilize and support intestinal function
Origin	Natural clay mineral (Hydrated magnesium aluminum silicate)

Smecta is categorized primarily as an Intestinal Adsorbent and a Gastrointestinal Protectant, placing it within the broader pharmacological classification of anti-diarrheal agents. The active ingredient, Diosmectite, functions locally, exhibiting a non-systemic action, meaning it is not absorbed into the bloodstream. This characteristic, which is highly valued in clinical settings, is fundamental to its mechanism. The medication is clinically recognized for its role in mitigating the symptoms of acute gastrointestinal distress, offering a mechanical approach to intestinal stabilization.

Diosmectite: Composition, Origin, and Dosage Form

The core component is Diosmectite (Dioctahedral Smectite), which is defined as a purified natural hydrated magnesium aluminum silicate. Its classification as a natural clay mineral derived from silicates distinguishes its origin from purely synthetic compounds. Diosmectite is a substance used to bind toxins and provide a protective effect on the digestive mucosa. This dual function involves cleansing the gut while simultaneously shielding the intestinal lining. Unlike some other adsorbents, Smecta is widely recognized for its presentation as a powder for oral suspension, typically packaged in individual sachets and often formulated with flavors to enhance patient acceptability. This dosage form, delivered via the oral route, is critical as the resultant uniform aqueous suspension maximizes the active substance's surface area for mucosal contact.

How Does Diosmectite Function as a Mechanical Barrier?

Diosmectite exerts its effects through a physical, mechanical barrier mechanism. Its unique structure enables physical adsorption, which is the capacity to trap and bind various damaging agents, including toxins and pathogens, directly onto the surface of the mineral particles. Furthermore, Diosmectite provides significant protection against the aggressive factors that cause intestinal damage. This underscores the medication's role in helping to maintain the physical integrity of the gut wall. This two-fold action provides a direct, protective shield that aids in settling the digestive system and restoring the physical integrity of the intestinal surface.

What side effects are possible with Smecta (Bentonite)?

Possible side effects and safety information

The safety profile of Diosmectite, the active ingredient in Smecta, is characterized by adverse reactions primarily documented in the gastrointestinal and immune systems, reflecting its non-systemic, local action. All documented effects and classifications are derived strictly from official government regulatory sources.

Officially Documented Adverse Reactions by Frequency

Adverse reactions are classified according to standard regulatory conventions:

Frequency Classification	Documented Adverse Reactions
Common (1/100 to < 1/10)	Constipation
Uncommon (1/1,000 to < 1/100)	Rash, Urticaria (Hives), Vomiting
Not Known	Angioedema, Pruritus (Itching), Hypersensitivity

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions

While the medicine is not systemically absorbed, potentially serious hypersensitivity reactions are noted in official labeling. Angioedema, a severe allergic reaction, is classified under Immune System Disorders.

Dose and Population Patterns

The most common adverse effect, Constipation, is noted as dose-dependent. In the pediatric population, constipation may be observed more frequently but typically resolves upon dose reduction. The official regulatory documents caution that chronic use of the medicine should be avoided.

Safety Restrictions

Due to its high adsorbent capacity, Diosmectite may interfere with the absorption of other orally administered medicinal products. The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or any excipients, as listed in the regulatory documents.

Overdose and Emergency Response

The official regulatory profile for Diosmectite (Smecta) overdose is directly defined by the non-systemic nature of its active ingredient, an intestinal adsorbent. As stated in official prescribing information, there is no experience of overdosage formally documented, which means severe, life-threatening, or systemic outcomes are not described in the context of overexposure. The regulatory basis for the overdose profile is therefore constrained to local effects.

Documented Manifestations

According to official labeling, the clinical manifestations of overdose are limited to the product's high-adsorption capacity within the gastrointestinal tract. Excessive consumption has the potential to lead to local complications, specifically severe constipation and, in documented cases, the formation of a bezoar. These are the key physical presentations of an overexposure scenario.

Required Emergency Actions and Management

Regulators mandate clear emergency-response statements in the event of suspected overdosage. Patients must consult a doctor or pharmacist immediately. If these avenues are unavailable, it is required to contact the nearest hospital or a poison centre for guidance. Management of the overexposure is officially defined as symptomatic management is indicated. The official documentation explicitly confirms that no specific antidote is known or available for Diosmectite, connecting the required supportive management to this regulatory fact.

Therapeutic Uses of Smecta (Bentonite)

What Smecta (Bentonite) Treats: Main Uses and Benefits

Quick Facts

Addresses: Symptoms of acute and chronic diarrhea.
Observed effect: May reduce the duration and frequency of bowel movements.
Therapeutic role: Functions as an adjunctive treatment to help manage gastrointestinal discomfort.

Smecta, which contains the active ingredient diosmectite (a type of bentonite clay), is indicated for the management of symptoms associated with acute and chronic diarrhea. This medication is often used to help reduce the duration of an acute diarrheal episode and may contribute to a decrease in the frequency of bowel movements.

It is considered an adjunctive therapy, meaning it is used in addition to essential supportive measures, such as oral rehydration solutions, to help replace fluids and electrolytes lost during diarrhea. When administered, the compound is observed to interact with the intestinal lining, which may help to promote the improvement of stool consistency.

Clinical information suggests that the use of this type of adsorbent clay can provide symptomatic relief in both adults and children experiencing mild-to-moderate diarrhea.

Eligibility and Restrictions for Use

Eligibility for Smecta (Dioctahedral Smectite) — Official Restrictions

Official restrictions on the use of Smecta (dioctahedral smectite, a type of clay) are defined primarily by age and physiological state, largely due to precautionary measures regarding the potential for trace amounts of naturally occurring heavy metals, such as lead, in the clay source.

Population Group	Official Eligibility Status
Adults	Use is allowed for the restricted indication of acute diarrhea.
Children ge 2 years of age	Use is allowed for the restricted indication of acute diarrhea.
Infants/Children < 2 years	Use is not recommended and should be avoided. Oral rehydration solution (ORS) is the reference treatment for acute diarrhea in this age group.
Pregnant Women	Use is not recommended (precautionary measure due to lack of data on systemic absorption).
Breastfeeding Women	Use is not recommended (precautionary measure due to lack of data on systemic absorption).

Contraindications and Special Considerations

Formal contraindications based on clinical conditions are generally not explicitly stated in regulatory warnings regarding the trace lead content. However, the product is contraindicated for individuals with known hypersensitivity (allergy) to the active substance or any of the excipients. It is generally advised that individuals with severe chronic constipation should avoid this medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Smecta (Diosmectite) is dictated by its function as a non-systemic intestinal adsorbent. Because the active ingredient is not absorbed into the bloodstream, interactions related to drug metabolism (such as those involving CYP enzymes) or drug transporters are not officially documented in regulatory information.

Officially Documented Interaction Pattern

The sole documented interaction is physical interference with the absorption of co-administered substances. The high adsorbent capacity of the clay mineral can bind to other medicinal products within the gastrointestinal tract, potentially reducing the absorption time and/or rate of those substances.

Timing Restrictions and Separations

To prevent reduced efficacy of other treatments, official regulatory documents establish mandatory separation rules. It is formally recommended that all other oral medicines be administered at least two hours before the administration of Smecta. This ensures sufficient time for the other medicine's absorption prior to the introduction of the adsorbent material. The concurrent administration of any other medicinal product is restricted.

Summary of Regulatory Status

Classification	Regulatory Status
Contraindicated Combinations	None formally documented due to interaction.
Metabolic (PK) Interactions	Not documented (non-systemic action).
Food or Alcohol Interactions	No specific formal warnings or restrictions documented.

Mechanism of Action

The mechanism of Diosmectite is entirely local and non-systemic, relying on the mineral’s structural properties to exert multifaceted actions within the gastrointestinal tract.

️ Physical Shielding and Mucosal Barrier Reinforcement

The primary action involves the physical adhesion of Diosmectite to the intestinal mucus layer, particularly by interacting with Mucin 2 (MUC2), which thickens and strengthens the natural barrier. This barrier reinforcement provides immediate cytoprotection, shielding the epithelial cells from aggressive luminal contents and thereby reducing the stimulation of the gut wall by irritants. This action is crucial for preserving the structural integrity of the gut wall at the epithelial level, supporting the physiological regulation of local intestinal processes.

High-Capacity Adsorption of Irritants and Water

Diosmectite's vast surface area and layered structure enable physical adsorption of various substances in the gut lumen, including water, bacterial toxins, and viral enterotoxins (like NSP4). This mechanism neutralizes the damaging factors and limits the volume of free water, which contributes to affecting the movement of fluid across the epithelium and limiting the direct interaction of irritants with the underlying tissue.

⬇️ Local Pathway Attenuation

By physically neutralizing irritants and protecting the cellular lining from damage, the mechanism indirectly attenuates local inflammatory pathways, suppressing the release of pro-inflammatory mediators. This protective cascade also reduces the overstimulation of afferent nerve fibers, which decreases the signaling input from afferent nerve fibers and results in a modulated local signaling environment within the intestinal wall.

Dosage and Administration Information

The use of Diosmectite (Smecta) is governed by specific instructions for administration, dosing, and timing.

Official Administration and Preparation

Diosmectite is administered via the oral route as a 3 g powder for oral suspension. To ensure proper use, the contents of the sachet must be mixed thoroughly with a liquid immediately before ingestion to form a uniform suspension.

Adult Preparation: Typically diluted in half a glass of water.
Pediatric Preparation: The powder can be mixed in a 50 ml feeding bottle of water or with semi-liquid food, such as purée, compote, or broth, to be taken throughout the day.

Standard Labeled Dosing Regimens

Population	Acute Diarrhea Dosage	Other Uses (e.g., Bowel Discomfort)	Treatment Duration
Adults	3 sachets per day for 7 days (dose may be doubled at the beginning of treatment to 6 sachets/day)	3 sachets per day	Up to 7 days
Children ge 2 years	4 sachets per day for 3 days, then 2 sachets per day for 4 days	Not typically recommended	Up to 7 days

Timing and Procedural Rules

Correct timing relative to meals and other medications is important for administration:

Timing: The medicine should generally be taken between meals. For specific uses, such as pain associated with oesophageal disorders, administration is recommended after meals.
Drug Separation: Due to its adsorbent properties, Diosmectite may interfere with the absorption of other oral medicines. A necessary separation of at least two hours is recommended between the intake of Diosmectite and any other drug.
Duration: If symptoms of acute diarrhea do not improve after 7 days of treatment, it is recommended to consult a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Smecta (Bentonite)

Evidence from Studies on Acute Diarrhea

Research has studied diosmectite primarily through meta-analyses that pool data from numerous short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time during an acute episode. The main focus of this research examined specific outcomes such as the total time required for diarrhea to resolve, the rate of clinical cure, and changes in stool consistency.

Studies reported that measurements of a shortened duration to diarrhea cessation were observed in some studies involving both children and adults. Regulatory and scientific bodies have noted that the certainty for these findings remains low to very low due to methodological issues in many of the included trials. Research has not extensively studied whether patterns exist concerning more serious outcomes, such as rates of hospitalization or need for intravenous rehydration.

Evidence from Studies on Chronic Functional Diarrhea

For chronic conditions, such as Diarrhea-Dominant Irritable Bowel Syndrome (IBS-D), research has primarily explored the effect using individual RCTs and observational settings evaluating daily-life functioning in adults. Key outcomes monitored in this research examined patient-reported outcomes describing perceived discomfort, changes in stool frequency, and stool consistency over defined time intervals. Scientific reviews indicate that the evidence for these symptomatic outcomes appears to be of moderate level.

However, the evidence is limited because studies often focus only on short-term or temporary physiological imbalance. The follow-up durations were limited, and there is limited information for long-term outcomes that would capture phases of heightened symptom activity over many months or years.

Research Focus on Special Populations

Research has been extensively evaluated in the pediatric population, particularly in infants and young children experiencing acute diarrhea. However, data for certain groups remain insufficient. For example, long-term effects are not fully established for older adults or individuals with certain comorbid conditions, as the research primarily examined acute episodes in otherwise generally healthy subjects.

Documented Research Gaps and Uncertainties

Despite the volume of research available, certainty remains low for several key outcomes, as documented by official reviews. The comparative evidence is lacking against other comparison medicines in large-scale, low-bias RCTs. This means that while research describes short-term symptomatic patterns, the overall picture of evidence for long-term use and comparison is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Smecta (Bentonite) (FAQ)

Q: How does Smecta interact with oral contraceptive pills?

Regulatory documents advise separation of the intake of all other oral medicines, including commonly used hormonal medicines such as oral contraceptives, by at least two hours from Smecta. This separation is specified due to the medicine's physical adsorption properties, which can bind to other substances in the gut and potentially affect their absorption.

Q: Does Smecta contain sugar or artificial sweeteners?

According to the official product labels, the formulation of Smecta powder includes excipients that can contain both sugar and artificial sweeteners. For example, some formulations list glucose (a type of sugar) and saccharin sodium (a sweetener). The full list of excipients is available in the Summary of Product Characteristics (SmPC) for the specific flavor being used.

Q: Does Smecta help with symptoms like heartburn or acid reflux?

Regulatory indications include the symptomatic treatment of pain associated with oesophageal disorders. Administration for this specific use is noted to be after meals. Official information notes this use for conditions associated with oesophageal discomfort.

Q: What are the ingredients in the Smecta flavorings?

The ingredients that make up the flavorings are listed as part of the excipients in the official Summary of Product Characteristics (SmPC). These excipients can include components such as propylene glycol E1520. The full list of these non-active components is available in the SmPC for each specific product formulation.

Q: Why is Smecta sold as a powder instead of a pill?

The medicine is officially formulated as a powder for oral suspension. Creating an aqueous suspension is intended to maximize the active substance’s surface area for physical contact with the intestinal mucus layer.

Q: Can Smecta reduce the absorption of nutrients from food?

Due to the medicine's high adsorbent nature, official guidance specifies administration between meals. This timing is used to avoid potential physical interference with the absorption of any co-administered substances, which could include the nutrients consumed with food.

Q: Does Smecta prevent or just relieve diarrhea symptoms?

Regulatory documents classify the medicine's use as the symptomatic treatment of acute diarrhea. This means it is used to manage or reduce the symptoms of acute diarrhea, as well as the pain associated with certain functional bowel diseases.

Q: Can Smecta be used in individuals who are lactose intolerant?

Some formulations of the medicine may contain lactose as an excipient (a non-active ingredient). If the user has known intolerances, such as lactose intolerance, the complete excipient list is available in the Summary of Product Characteristics (SmPC) to verify the contents of the specific product.

Q: How does Smecta work on different types of toxins in the gut?

The medicine's mechanism involves the physical adsorption of various damaging agents in the gut lumen. Regulatory documents specifically list the adsorption of both bacterial toxins and certain viral enterotoxins as part of its protective action.

Q: Does Smecta treatment change the natural gut flora?

Studies that have examined the impact over a short period (such as five weeks) suggest that the overall composition of the gut microbiota was not significantly altered in adults with chronic diarrhea. This research is based on the limited clinical trial data available.

Q: Are there special guidelines for using Smecta in patients with diabetes?

Because certain formulations of the medicine may contain glucose as an excipient, individuals should note that the full list of excipients is available in the Summary of Product Characteristics (SmPC) to determine the exact sugar content of the product.

How should Smecta (Bentonite) be stored and disposed of?

Storage and Disposal Requirements for Smecta (Diosmectite)

Official regulatory information outlines specific conditions for storing and discarding the powder for oral suspension to ensure product stability and safety.

Storage Conditions

The product must be stored below 25°C (77°F) and maintained in a dry place to protect the powder from moisture. The medicine should be kept out of the reach and sight of children. Users must observe the expiry date printed on the packaging, as the product must not be used after this date. Importantly, the prepared suspension, once mixed with water, must be used immediately.

Disposal Instructions

Unused or expired Smecta must not be disposed of via sinks, drains, or regular household waste. Regulatory guidelines mandate that users ask a pharmacist for guidance on proper disposal, ensuring the medicine is handled according to local pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.